Insider Buying: CNS Pharmaceuticals (NASDAQ:CNSP) Director Acquires 7,100 Shares of Stock

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Director Faith Charles acquired 7,100 shares of the stock in a transaction dated Monday, May 18th. The stock was purchased at an average cost of $4.79 per share, with a total value of $34,009.00. Following the purchase, the director directly owned 7,100 shares of the company’s stock, valued at $34,009. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

CNS Pharmaceuticals Stock Performance

Shares of CNS Pharmaceuticals stock traded up $0.02 on Wednesday, hitting $4.80. The stock had a trading volume of 17,424 shares, compared to its average volume of 938,792. The stock has a 50 day moving average of $3.25 and a 200 day moving average of $4.86. CNS Pharmaceuticals, Inc. has a twelve month low of $1.90 and a twelve month high of $15.73. The firm has a market capitalization of $3.88 million, a P/E ratio of -0.16 and a beta of 2.62.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its quarterly earnings data on Thursday, May 14th. The company reported ($7.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($8.82) by $1.52.

Institutional Trading of CNS Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Boothbay Fund Management LLC acquired a new stake in CNS Pharmaceuticals during the 4th quarter valued at approximately $71,000. Ikarian Capital LLC acquired a new stake in CNS Pharmaceuticals during the 4th quarter valued at approximately $241,000. Finally, Armistice Capital LLC acquired a new position in CNS Pharmaceuticals in the second quarter valued at approximately $335,000. Institutional investors and hedge funds own 14.02% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.00.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.